Targets › ND4
3 programs from 3 companies in 4 trials: 2 Phase 2, 1 Phase 1, 1 Phase 3; Neurology, Ophthalmology; next expected readout Feb 2028.
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor. Essential for the catalytic activity and assembly of complex I. (UniProt, P03905)
Open in Phaseline: the race on ND4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Wuhan Neurophth Biotechnology Limited Company | rAAV2-ND4 (NR082) Recombinant adeno-associated virus serotype 2 delivering wild-type ND4 gene for mitochondr | ND4 | Phase 3 | Leber Hereditary Optic Neuropathy (LHON); Leber's Hereditary Optic Neuropathy (LHON) | Feb 2028 |
| GenSight Biologics | GS010 (lenadogene nolparvovec, Lumevoq) AAV5-delivered ND4 gene replacement therapy for LHON | ND4 | Phase 2 | Leber Hereditary Optic Disease | May 2028 |
| Neurophth Therapeutics Inc | NR082 Injection Gene therapy for mitochondrial ND4 mutation replacement | ND4 | Phase 1 | Leber Hereditary Optic Neuropathy (LHON) | Dec 2029 |
Leber Hereditary Optic Neuropathy (LHON) (2) Leber Hereditary Optic Disease (1) Leber's Hereditary Optic Neuropathy (LHON) (1)
other (2), small molecule (1)
GenSight Biologics (1) Neurophth Therapeutics Inc (1) Wuhan Neurophth Biotechnology Limited Company (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.